問卷

TPIDB > Search Result

Search Result

篩選

List

23Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2024-01-01 - 2040-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-06-20 - 2027-09-01

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-01-06 - 2026-09-05

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Recruiting14Sites

2020-05-01 - 2024-04-15

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2020-09-15 - 2025-10-08

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2022-05-10 - 2026-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-09-03 - 2027-08-09

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2022-12-01 - 2026-06-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-12-01 - 2028-12-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

1 2 3